Peptides: BPC-157 FDA Status — Myth vs. Fact

The regulatory status of BPC-157 is frequently mischaracterized in both directions — some sources claim it is “banned,” implying criminal possession; others dismiss any regulatory concern. The reality is more precise and worth understanding clearly.

What the FDA Actually Did

2015 — Nomination

BPC-157 was nominated for inclusion on the FDA’s 503B bulk drug substances list. Section 503B of the Food, Drug, and Cosmetic Act governs outsourcing facilities (large-scale compounding pharmacies). Being on this list would allow compounding pharmacies to legally produce BPC-157 as a compounded medication.

2019 — Category 2 Placement

FDA placed BPC-157 in Category 2 of the 503B bulk drug substance evaluation — meaning FDA determined there was “insufficient evidence of clinical usefulness.” This placed compounding pharmacies in a gray zone where BPC-157 use was not explicitly approved but not yet finally prohibited.

2023 — Final Rule

The FDA published its final rule removing BPC-157 from the 503B bulk drug substances list. This is a definitive regulatory prohibition: compounding pharmacies that operate as 503B outsourcing facilities cannot include BPC-157 as an active ingredient in compounded medications. This rule is currently in effect.

What This Does NOT Mean

Action	Year	What It Means	What It Does NOT Mean
503B Category 2 placement	2019	FDA found insufficient clinical usefulness evidence	BPC-157 is not automatically banned; no possession prohibition
503B final rule removal	2023	Compounding pharmacies (503B) cannot use BPC-157	Does not schedule it; does not criminalize possession
WADA S2 prohibition	2024 list	Athletes subject to WADA rules cannot use BPC-157	Non-athletes are not bound by WADA rules
DEA scheduling (none)	N/A	BPC-157 is not on DEA Schedule I–V	Possession is not a federal criminal drug offense
FDA approval (none)	N/A	No approved therapeutic product exists	Does not make possession illegal

Legal Status by Jurisdiction

Jurisdiction	Status	Schedule	Notes
USA	Research chemical	None (DEA unscheduled)	503B compounding banned 2023; possession legal; “not for human use” label required
UK	Not licensed	Not scheduled under Misuse of Drugs Act	No approved pharmaceutical product; importation for personal use in gray area
Australia	Prescription required	Schedule 4 (Prescription Only)	ASADA prohibited for athletes; requires physician prescription for legal possession
Canada	Gray market	No DIN (Drug Identification Number)	Not approved by Health Canada; gray market research chemical
EU	Varies by country	No harmonized EU status	Generally unscheduled; some countries may classify differently; no EMA-approved product

The WADA Prohibition

For competitive athletes, WADA’s S2 classification is the most immediately relevant regulatory fact. BPC-157 appears on the WADA Prohibited List under “S2 — Peptide Hormones, Growth Factors, Related Substances and Mimetics.” This prohibition applies in-competition and out-of-competition. Athletes who compete under anti-doping agreements — including most professional and Olympic-level sports — cannot use BPC-157 regardless of its legal status in their jurisdiction.

WADA’s inclusion of a substance does not prove efficacy. WADA takes a precautionary approach based on plausible performance-enhancing mechanism, not confirmed human RCT data.

The Evidence Context

BPC-157 has never completed a human Phase 1, 2, or 3 clinical trial as of 2026. The extensive animal data from the Sikiric laboratory at the University of Zagreb is real and detailed, but the transition from rat study to regulatory approval requires human trials. The FDA’s Category 2 classification and subsequent removal from the 503B list reflects this evidence gap, not a finding of harm.